VIM and metastatic neoplasm: Indeed, we were able to identify many more VIM+ CTCs relative to CK+ CTCs, and this technological feasibility, combined with the greater potential biological relevance of mesenchymal or mixed E/M-phenotype CTCs in patients with metastatic disease, suggests that analysis of this CTC population may enable generation of more statistically robust and informative data in future studies.